Definium Therapeutics, Inc.
DFTX
$42.63
-$1.27-2.89%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -106.21% | -52.86% | 25.02% | -57.37% | -83.07% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 244.34% | 147.01% | -60.31% | 485.48% | 240.06% |
| Change in Net Operating Assets | 15.35% | 227.08% | -152.95% | 0.09% | 428.69% |
| Cash from Operations | -23.80% | 0.80% | -45.35% | 0.11% | -0.61% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -854.14% | 20.05% | 127.08% | 138.97% | 75.66% |
| Cash from Investing | -854.14% | 20.05% | 127.08% | 138.97% | 75.66% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | 15,132.32% | -97.97% | 34,855.14% | 672.16% | -90.32% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Financing | 14,258.00% | -97.84% | 32,726.17% | -96.19% | 1,861.08% |
| Foreign Exchange rate Adjustments | -133.33% | 200.00% | 104.76% | -184.00% | 308.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8,290.28% | -98.03% | 1,870.85% | 72.84% | 74.09% |